Last updated 4 months ago
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
800 patients around the world
Pfizer
800Patients around the world
This study is for people with
Colorectal cancer
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- Histological or cytological confirmed colorectal adenocarcinoma.Evidence of Stage IV metastatic disease.Eastern Cooperative Oncology Group performance status (ECOG) 0-1.At least one measurable lesion according to RECIST 1.1 per Investigator assessment.Adequate hepatic, liver, and renal function.
- Locally confirmed BRAF V600E mutation.Locally confirmed microsatellite instability (MSI)-high or DNA mismatch repair deficiency (dMMR) colorectal cancer.Participants with known active symptomatic CNS lesions, including leptomeningeal metastasis, brainstem, meningeal, or spinal cord metastases or compression.Clinically significant risk of hemorrhage or fistula.Major surgery or severe trauma within 4 weeks prior to the first dose, or planned major surgery during the study.History of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.Any Grade ≥3 bleeding/hemorrhage events within 28 days of Cycle 1 Day 1, or prior history of clinically significant bleeding events.Clinically significant cardiovascular disease, or other comorbidities, within 6 months prior to first dose.Participants with active autoimmune diseases requiring systemic treatment within the past 2 years.Evidence of non-infectious or drug-induced interstitial lung disease (ILD) pneumonitis.
SponsorPfizer
Study typeInterventional
Conditions
Colorectal cancer
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT07222800
